36 completed, 20 unknown, 17 recruiting, 6 not yet recruiting. 36 Phase 4, 22 Phase 2, 16 Phase 3, 7 Not applicable, 7 Phase 1.
Follow Jardiance: new trials by email Literature Review of Jardiance trials Research Report on Jardiance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction Jardiance, non-SGLT2 inhibitors - Heart Failure of Reduced Ejection Fraction (HFrEF) | Not yet recruiting | Boehringer Ingelheim | 5000 | 2028-01-31 | 2026-09-15 | |
| SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD | Phase 2 | Not yet recruiting | Justin Ryder | 40 | 2027-05-01 | 2026-01-20 |
| Vascular Effects of SGLT2i in Non-diabetic CKD Empagliflozin, Placebo - Non-diabetic Chronic Kidney Disease | Phase 2 | Not yet recruiting | VA Office of Research and Development | 52 | 2026-10-01 | 2026-08-20 |
| Role of Finerenone in African American Veterans With Diabetic Kidney Disease Finerenone 10 MG, Empagliflozin 10 MG - Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Washington D.C. Veterans Affairs Medical Center | 30 | 2026-10-01 | 2026-08-21 |
| Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients empagliflozin, Placebo - ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI) | Phase 2 | Not yet recruiting | Rehman Medical Institute - RMI | 480 | 2026-09-01 | 2026-08-06 |
| SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial Empagliflozin 10 mg, Placebo - Gout and Hyperuricemia | Phase 4 | Recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-08-05 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Empagliflozin Adjunctive Therapy in Bipolar Depression Empagliflozin (EMPA) - Bipolar Disorder, Bipolar Depression | Not applicable | Not yet recruiting | University of Sao Paulo | 20 | 2026-03-09 | 2026-03-16 |
| Randomized Trial of SGLT2i in Heart Transplant Recipients Empagliflozin, Placebo - Heart Transplant, Cardiovascular Disease | Phase 4 | Recruiting | VA Office of Research and Development | 200 | 2026-01-20 | 2026-01-22 |
| A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) Empagliflozin, Placebo - Chronic Kidney Disease | Phase 3 | Active not recruiting | Boehringer Ingelheim | 135 | 2025-12-09 | 2026-10-14 |
| Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI Flozin - Coronary Artery Disease, Acute Kidney Injury | Recruiting | Collegium Medicum w Bydgoszczy | 4000 | 2025-11-01 | 2025-11-17 | |
| Feasibility Trial for a Right Ventricular Failure Platform Trial Empagliflozin, Ranolazine - Pulmonary Hypertension, Right Ventricular Dysfunction | Phase 2 | Recruiting | University of Alberta | 30 | 2025-07-15 | 2026-10-15 |
| Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension Empagliflozin 10 MG, Placebo - Pulmonary Arterial Hypertension | Phase 2 | Recruiting | Gustavo A Heresi, MD, MS | 78 | 2025-06-26 | 2026-08-13 |
| SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia Empagliflozin 25 MG - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 29 | 2025-04-29 | 2026-07-17 |
| HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy Carvedilol, Empagliflozin - HER2-positive Breast Cancer, HER2+ Breast Cancer | Phase 2 | Terminated | Washington University School of Medicine | 7 | 2025-04-16 | 2026-05-13 |
| Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease | Phase 2 | Recruiting | Justin Ryder | 40 | 2025-04-10 | 2026-01-21 |
| Efficacy of SGLT2 Inhibitors in Adults With Sepsis Empagliflozin 10 MG, Placebo - Sepsis, Inflammation | Not applicable | Recruiting | Hospital Authority, Hong Kong | 60 | 2025-03-05 | 2025-03-19 |
| SGLT2i, Hepatic Glucose Production, and SNS Empagliflozin 25 MG - Type 2 Diabetes | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 22 | 2025-01-07 | 2026-07-17 |
| Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs Tirzepatide (Mounjaro), dapagliflozin, empagliflozin, metformin - Heart Failure, Diabete Type 2 | Not applicable | Active not recruiting | Nazarbayev University | 120 | 2024-12-18 | 2026-01-28 |
| Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes Oral semaglutide, Empagliflozin 10 mg - Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 90 | 2024-10-01 | 2026-04-30 |
Showing 20 of 95. Sign in to see all of them.
Diabetes Mellitus, Type 2 (31) · Diabetes Mellitus (12) · Heart Failure (10) · Non-alcoholic Fatty Liver Disease (7) · Renal Insufficiency, Chronic (7) · Diabetic Nephropathies (4) · Albuminuria (3) · Cardiovascular Diseases (3) · Coronary Artery Disease (3) · Obesity (3) · Cardiotoxicity (2) · Glycogen Storage Disease IB (2) · Glycogen Storage Disease Type I (2) · Hypertension (2) · Inflammation (2)
The University of Texas Health Science Center at San Antonio (5) · Boehringer Ingelheim (3) · VA Office of Research and Development (3) · Centro Universitario de Ciencias de la Salud, Mexico (2) · Justin Ryder (2) · NYU Langone Health (2) · Profil Institut für Stoffwechselforschung GmbH (2) · RWTH Aachen University (2) · Unity Health Toronto (2) · Washington University School of Medicine (2) · Yonsei University (2) · Ain Shams University (1) · Amsterdam UMC, location VUmc (1) · Aristotle University Of Thessaloniki (1) · Asan Medical Center (1)
United States (29) · Germany (9) · Poland (7) · Netherlands (6) · South Korea (6) · Canada (5) · United Kingdom (5) · Belgium (3) · China (3) · Denmark (3) · Italy (3) · Mexico (3) · Austria (2) · France (2) · Hong Kong (2)
Ralph DeFronzo, MD (4) · Justin Ryder, PhD (2) · Anna Borowiec, PhD (1) · Ashraf S Niazi, MBBS, FRCP (1) · Bassem Zarif, MD (1) · Beny Lafer, MD, PhD (1) · Carlos Guizar-Sanchez, MD (1) · Carolina Solis-Herrera, MD (1) · Caroline M Kistorp, MD, PhD. (1) · Dan V Iosifescu, MD, MMSc (1) · Daniel van Raalte, MD PhD (1) · David Charytan, MS, MSc (1) · Dinesh Kalra, MD (1)
PMID 32803882, PMID 21094444, PMID 22431131, PMID 23398530, PMID 23906374, PMID 26555703, PMID 28605608, PMID 28606345, PMID 28923906, PMID 29042392, PMID 29802538, PMID 29895557, PMID 30231923, PMID 30415602, PMID 30520545, PMID 30559238, PMID 30585690, PMID 30586745, PMID 30684076, PMID 30862658, PMID 30866088, PMID 30922297, PMID 30990260, PMID 31081589, PMID 31434508, PMID 31769309, PMID 31780586, PMID 31843945, PMID 32501595, PMID 32567439, PMID 32827752, PMID 32865004, PMID 32865377, PMID 32994273, PMID 33004472, PMID 33186500, PMID 33447845, PMID 33454272, PMID 33550815, PMID 33832352, PMID 34607574, PMID 34693515, PMID 34696602, PMID 34939776, PMID 34991562, PMID 35061894, PMID 35387874, PMID 35391843, PMID 35441435, PMID 35572519
2016 (4), R01DK024092 (3), 2017 (1), 2019 (1), 2023 (1), R01DK107680 (1), R61AR084188 (1), UG3HL175041 (1), UH3HL175041 (1)